Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Behçet's syndrome: providing integrated care.
Esatoglu SN, Kutlubay Z, Ucar D, Hatemi I, Uygunoglu U, Siva A, Hatemi G. Esatoglu SN, et al. Among authors: kutlubay z. J Multidiscip Healthc. 2017 Aug 14;10:309-319. doi: 10.2147/JMDH.S93681. eCollection 2017. J Multidiscip Healthc. 2017. PMID: 28860798 Free PMC article. Review.
Biosimilar infliximab for Behçet's syndrome: a case series.
Dincses E, Esatoglu SN, Ozguler Y, Uygunoglu U, Hamuryudan V, Seyahi E, Melikoglu M, Fresko I, Ucar D, Ozyazgan Y, Kutlubay Z, Mat MC, Yurdakul S, Siva A, Hatemi G. Dincses E, et al. Among authors: kutlubay z. Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 121(6):111-115. Epub 2019 Dec 9. Clin Exp Rheumatol. 2019. PMID: 31856937 Free article.
Emergence of new manifestations during infliximab treatment in Behçet's syndrome.
Tukek NB, Esatoglu SN, Hatemi G, Calıskan EB, Ozyazgan Y, Ucar D, Ozguler Y, Seyahi E, Melikoglu M, Uygunoglu U, Siva A, Kutlubay Z, Hatemi İ, Celik AF, Ugurlu S, Fresko I, Yurdakul S, Yazici H, Hamuryudan V. Tukek NB, et al. Among authors: kutlubay z. Rheumatology (Oxford). 2022 Aug 30;61(9):3746-3753. doi: 10.1093/rheumatology/keab944. Rheumatology (Oxford). 2022. PMID: 34958357
Infliximab for vascular involvement in Behçet's syndrome.
Hatemi G, Tukek NB, Esatoglu SN, Ozguler Y, Taflan SS, Uygunoglu U, Melikoglu M, Ugurlu S, Fresko I, Siva A, Kutlubay Z, Yurdakul S, Yazici H, Hamuryudan V. Hatemi G, et al. Among authors: kutlubay z. Clin Immunol. 2023 Aug;253:109682. doi: 10.1016/j.clim.2023.109682. Epub 2023 Jun 28. Clin Immunol. 2023. PMID: 37385325
De novo manifestations during adalimumab treatment in Behçet's syndrome.
Esatoglu SN, Sonmez O, Ucar D, Kaymaz E, Ozguler Y, Ugurlu S, Seyahi E, Melikoglu M, Fresko I, Hamuryudan V, Uygunoglu U, Kutlubay Z, Hatemi AI, Celik AF, Hatemi G. Esatoglu SN, et al. Among authors: kutlubay z. Rheumatology (Oxford). 2024 Aug 7:keae416. doi: 10.1093/rheumatology/keae416. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39110537
102 results